MedTrace Logo

Immunomonitoring of Breast Cancer Patients During Systemic Treatment

NCT04925856 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-10-17

No results posted yet for this study

Summary

This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.

Conditions

Interventions

OTHER

blood sample

•Blood sample: * 1 heparinized tube (4 mL) for collection of plasma and storage * 1 heparinized tube (4 mL) for immunophenotyping, * 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation.

Sponsors & Collaborators

  • Centre Georges Francois Leclerc

    lead OTHER

Principal Investigators

  • Sylvain LADOIRE, PU-PH · Centre Georges François Leclerc

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2030-05-26
Completion
2030-05-26

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04925856 on ClinicalTrials.gov